Methylphenidate: Difference between revisions
From Pharmacopedia
More actions
| [checked revision] | [checked revision] |
parser-claude (pharmacist-claude hat): citation pass + content fills per Mark go 2026-05-26. Adds: history section (Panizzon 1944, Ciba launch, Schedule II 1971, MTA study, Cooper 2011 CV outcomes), Cortese 2018 NMA in intro, FDA warning refs (4), references/> infrastructure, FDA Ritalin label ref on PK, Ritalin IR indication clarification, MPH-TCA interaction revision, anecdote typo fix. |
MDElliottMD (talk | contribs) B3 edit-4: Molina 2009 ref for MTA long-term claim (PMID 19318991); en-dash re-anchor; home-claude, mark-greenlit |
||
| Line 22: | Line 22: | ||
Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use. | Methylphenidate was placed on Schedule II of the U.S. Controlled Substances Act in 1971, alongside amphetamine and cocaine, where it has remained.<ref name="csa-1971">U.S. Drug Enforcement Administration. Controlled Substances Act (21 U.S.C. §§ 801–971), Schedule II. 21 CFR 1308.12.</ref> The 1990s and 2000s saw a marked expansion of ADHD diagnosis and methylphenidate prescribing in the United States, accompanied by the development of extended-release formulations (Concerta osmotic-pump tablets approved 2000; Ritalin LA 2002; Metadate CD 2001; Daytrana transdermal patch 2006) that reduced the practical burden of multiple-times-daily dosing and supported broader adult use. | ||
The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood. | The largest independent comparative-effectiveness data source on methylphenidate is the Multimodal Treatment of ADHD (MTA) study, a National Institute of Mental Health-funded randomized controlled trial published in 1999 that compared medication management (predominantly methylphenidate), behavioral therapy, the combination of both, and community standard care in 579 children aged 7–9 with ADHD. The medication and combined arms produced significantly greater improvement in ADHD symptoms than the behavioral or community arms at 14 months.<ref name="mta1999">MTA Cooperative Group. A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry. 1999;56(12):1073–1086.</ref> Long-term follow-ups have moderated the short-term superiority finding, with diminishing between-group differences by 36 months and broadly comparable functional outcomes across arms by adulthood.<ref name="molina2009">Molina BSG, Hinshaw SP, Swanson JM, et al. The MTA at 8 years: prospective follow-up of children treated for combined-type ADHD in a multisite study. J Am Acad Child Adolesc Psychiatry. 2009;48(5):484-500. PMID 19318991.</ref> | ||
Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place. | Cardiovascular safety in long-term outpatient use was characterized by Cooper and colleagues in a large 2011 cohort study published in the New England Journal of Medicine: among 1,200,438 children and young adults receiving ADHD medications, no significant association with serious cardiovascular events was found compared with non-users, after adjustment for cardiovascular risk factors.<ref name="cooper2011">Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. New England Journal of Medicine. 2011;365(20):1896–1904.</ref> A companion JAMA study by Habel and colleagues reached similar conclusions in adults.<ref name="habel2011">Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306(24):2673–2683.</ref> These analyses attenuated the post-2006 cardiac-safety concerns that had driven the peripheral vasculopathy and sudden-cardiac-death warnings, though the FDA warnings remain in place. | ||